Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43 - PubMed (original) (raw)

Review

Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43

Ian R A Mackenzie et al. J Mol Neurosci. 2011 Nov.

Abstract

Most cases of frontotemporal lobar degeneration (FTLD) are characterized by the abnormal accumulation of either the microtubule-associated protein tau or the transactive response DNA-binding protein with M(r) 43 kDa, TDP-43 (FTLD-tau and FTLD-TDP, respectively). However, there remain ∼10% of cases, composed of a heterogenous collection of uncommon disorders, for which the molecular basis remains uncertain. In this review, we describe the characteristic genetic, clinical, and pathological features of the major tau/TDP-negative FTLD subtypes, with focus on recent advances in our understanding of their molecular basis. This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.

PubMed Disclaimer

Similar articles

• A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
  Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schrøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. Lashley T, et al. Brain. 2011 Sep;134(Pt 9):2548-64. doi: 10.1093/brain/awr160. Epub 2011 Jul 12. Brain. 2011. PMID: 21752791 Free PMC article.
• Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies.
  Koga S, Murakami A, Soto-Beasley AI, Walton RL, Baker MC, Castanedes-Casey M, Josephs KA, Ross OA, Dickson DW. Koga S, et al. Acta Neuropathol Commun. 2023 Jul 6;11(1):109. doi: 10.1186/s40478-023-01611-z. Acta Neuropathol Commun. 2023. PMID: 37415197 Free PMC article.
• Frontotemporal lobar degeneration: diversity of FTLD lesions.
  Seilhean D, Bielle F, Plu I, Duyckaerts C. Seilhean D, et al. Rev Neurol (Paris). 2013 Oct;169(10):786-92. doi: 10.1016/j.neurol.2013.07.015. Epub 2013 Sep 12. Rev Neurol (Paris). 2013. PMID: 24035575 Review.
• Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.
  Halliday G, Bigio EH, Cairns NJ, Neumann M, Mackenzie IR, Mann DM. Halliday G, et al. Acta Neuropathol. 2012 Sep;124(3):373-82. doi: 10.1007/s00401-012-1030-4. Epub 2012 Aug 10. Acta Neuropathol. 2012. PMID: 22878865 Free PMC article. Review.

Cited by

• Pathomorphological Diagnostic Criteria for Focal Cortical Dysplasias and Other Common Epileptogenic Lesions-Review of the Literature.
  Metodiev D, Minkin K, Ruseva M, Ganeva R, Parvanov D, Nachev S. Metodiev D, et al. Diagnostics (Basel). 2023 Mar 31;13(7):1311. doi: 10.3390/diagnostics13071311. Diagnostics (Basel). 2023. PMID: 37046529 Free PMC article. Review.
• Pharmacotherapy for Frontotemporal Dementia.
  Khoury R, Liu Y, Sheheryar Q, Grossberg GT. Khoury R, et al. CNS Drugs. 2021 Apr;35(4):425-438. doi: 10.1007/s40263-021-00813-0. Epub 2021 Apr 11. CNS Drugs. 2021. PMID: 33840052 Review.
• Relevance of biomarkers across different neurodegenerative diseases.
  Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, Mattsson-Carlgren N, Ashton NJ, Hanrieder J, Zetterberg H, Schöll M, Paterson RW. Ehrenberg AJ, et al. Alzheimers Res Ther. 2020 May 13;12(1):56. doi: 10.1186/s13195-020-00601-w. Alzheimers Res Ther. 2020. PMID: 32404143 Free PMC article. Review.
• Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family.
  Sieben A, Van Mossevelde S, Wauters E, Engelborghs S, van der Zee J, Van Langenhove T, Santens P, Praet M, Boon P, Miatton M, Van Hoecke S, Vandenbulcke M, Vandenberghe R, Cras P, Cruts M, De Deyn PP, Van Broeckhoven C, Martin JJ. Sieben A, et al. Alzheimers Res Ther. 2018 Jan 22;10(1):7. doi: 10.1186/s13195-017-0334-y. Alzheimers Res Ther. 2018. PMID: 29370838 Free PMC article. Review.

References

1. 1. Eur J Neurol. 2010 Jul;17(7):969-75 - PubMed
2. 1. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1405-7 - PubMed
3. 1. Am J Pathol. 2004 Jun;164(6):2153-61 - PubMed
4. 1. Eur J Neurol. 2008 Jul;15(7):667-70 - PubMed
5. 1. Acta Neuropathol. 2009 Jan;117(1):15-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer